SAC Faces Insider Trading Probe on MedImmune  
6/1/2011 7:12:10 AM

SAC Capital Advisors LP faces an insider trading probe from the U.S. Securities and Exchange Commission related to the $15 billion takeover of biotechnology firm MedImmune Inc, the Wall Street Journal reported, citing people familiar with the matter.

The probe is part of a broader SEC inquiry into possible insider trading by hedge funds in connection with the biggest healthcare deals of the last decade, the Journal said.